The new compounds 1-aryl-3-{1-phenyl-3-[p-(methylthio)phenyl]pyrazol-4-yl}-2-propen-1-ones 2a-l were prepared by the condensation of 1-phenyl-3-[p-(methylthio)phenyl]-4-formylpyrazole 1 with different aryl ketones. Compounds 2a-l in reaction with hydrazine hydrate yielded 3-aryl-5-{1-phenyl-3-[p-(methylthio)phenyl]pyrazol-4-yl}-4,5-dihydro-(1H)-pyrazoles 3a-l and in the presence of hydrazine hydrate in glacial acetic acid gave 1-acetyl-3-aryl-5-{1-phenyl-3-[p-(methylthio)phenyl]pyrazol-4-yl}-4,5-dihydro-(1H)-pyrazoles 4a-l. These compounds were tested in vitro for their antitubercular and antimicrobial activities. The in vitro antimycobacterial activity of the newly synthesized compounds was investigated against Mycobacterium tuberculosis H 37 RV (ATCC 27294) in BACTEC 12B medium using the ALAMAR radiometric system. The antimicrobial in vitro activity was tested against Bacillus coccous, Bacillus subtilis, Escherichia coli, Proteus vulgaris and antifungal activity against Aspergillus niger. The structures of the synthesized compounds were assigned on the basis of elemental analysis, IR, 1 H NMR and mass spectral data.
INTRODUCTION
The synthesis of pyrazoles remains of great interest due to the wide applications of such heterocycles in the pharmaceutical and agrochemical industry. Pyrazole derivatives were reported to possess significant antibacterial, 1 p-38a MAP kinase inhibitory, 2 monoamine oxidase inhibitory activities, 3 insecticidal, 4 anticancer, 5 anti-HIV, 6 herbicidal, 7 etc. This gave a great impetus to the search for potential pharmacologically active drugs carrying pyrazole substituents.
Pyrazolyl pyrazoline derivatives were found to possess potent activities such as anti-inflammatory, 8 antimicrobial, 9 antiallergic, 10 antidiabetic, 11 cardiovascu-lar 12 and diuretic, 13 etc. The synthesis of a series of 3-aryl-5-{1-phenyl-3-[p-(methylthio)phenyl]pyrazol-4-yl}-4,5-dihydro-(1H)-pyrazoles 3a-l and 1-acetyl-3-aryl-5-{1-phenyl-3-[p-(methylthio)phenyl]pyrazol-4-yl}-4,5-dihydro-(1H)-pyrazoles 4a-l and their antitubercular and antimicrobial screening are reported.
3-Aryl-5-{1-phenyl-3-[p-(methylthio)phenyl]pyrazol-4-yl}-4,5-dihydro-(1H)-pyrazoles 3a-l and 1-acetyl-3-aryl-5-{1-phenyl-3-[p-(methylthio)phenyl]pyrazol-4-yl}-4,5-dihydro-(1H)-pyrazoles 4a-l were synthesized by treating 1-aryl-3-{1-phenyl-3-[p-(methylthio)phenyl]pyrazol-4-yl}-2-propen-1-ones 2a-l with hydrazine hydrate and hydrazine hydrate in glacial acetic acid, respectively (Scheme 1).
The structures of the synthesized compounds 2a-l, 3a-l and 4a-l were assigned on the basis of elemental analysis (Table I) as well as IR, 1 H NMR, and mass spectral data (Table II) . The bioassay indicated most of the synthesized compounds possessed significant growth promoting effects on various microbes. Under identical conditions, standard antibiotics showed zones of inhibition, such as ampicillin 20-24 mm, amoxicillin 21-25 mm, norfloxacin 18-25 mm, benzyl penicillin 15-20 mm, against bacterial strains and griseofulvin showed zones of inhibition of 18-24 mm against Aspergillus niger. None of the tested compounds showed significant in vitro antituberculosis activity at the 6.25 mg/mL level (MIC rifampin 0.25 mg/mL). 
EXPERIMENTAL
TLC was used to assess the reactions and the purity of the synthesized compounds. The melting points were determined in open capillary tubes and are uncorrected. The IR spectra were recorded on a Shimadzu FTIR-8400 instrument in a KBr disc and only noteworthy absorption levels (cm -1 ) are listed, 1 H NMR spectra on a Brucker AC-300 MHz FT NMR using TMS as the internal standard (chemical shifts in d, ppm), and mass spectra on a Jeol D-300 spectrophotometer. All the compounds gave satisfactory elemental analysis. Similarly, the other compounds 2a-l were prepared. Their characterization data are recorded in Table I and their spectral data in Table II . Similarly, the other compounds 3a-l were prepared. Their characterization data are recorded in Table I and their spectral data in Table II . Similarly, the other compounds 4a-l were prepared. Their characterization data are recorded in Table I and their spectral data in Table II .
Synthesis of 1-(
p-chlorophenyl)-3-{1-phenyl-3-[p-(methylthio)phenyl]pyrazol-4-yl}-2-propen-1-one (2b)
Synthesis of 3-(p-chlorophenyl)-5-{1-phenyl-3-[p-(methylthio)phenyl]pyrazol-4-yl}-4,5-dihydro-(1H)-pyrazole (3b)
A mixture of 1-(p-chlorophenyl)-3-{1-phenyl-3-[p-(methylthio)phenyl]pyrazol-4-yl}-2-pro- pen-1-one (4.
Synthesis of 1-acetyl-3-(p-chlorophenyl)-5-{1-phenyl-3-[p-(methylthio)phenyl]pyrazol-4-yl}-4,5-dihydro-(1H)-pyrazole (4b)
A mixture of 1-(p-chlorophenyl)-3-{1-phenyl-3-[p-(methylthio)phenyl]pyrazol-4-yl}-2-pro- pen-1-one (2.
RESULTS AND DISCUSSION

Antitubercular activity.
The antitubercular evaluation of the compounds was carried out at the Tuberculosis Antimicrobial Acquistition Co-ordinating Facility (TAACF), USA. All the compounds were screened against Mycobacterium tuberculosis strain H 37 Rv at a concentration of 6.25 mg/mL in BACTEC 12B medium using the ALAMAR radiometric system.
The antitubercular activity data were compared with the standard drug Rifampin at 0.25 mg/mL concentrations, which showed 98 % inhibition (Table III) .
Antimicrobial activity.
The antimicrobial activity was assayed using the cup-plate agar diffusion method 14 by measuring the zone of inhibition in mm. All the compounds were SOME PYRAZOLE DERIVATIVES 717 rison purposes. The results are given in Table III , from where it can be seen that the compounds 3b, 3d, 3k, 4f, 4j and 4l were active against B. coccous, the 3b, 3f, 3k,  3l, 4e, 4g, 4i and 4l against B. subtilis, the compounds 3b, 3f, 3l, 4g, 4h, 4j and 4k  against E. coli, the compounds 3d, 3e, 3g, 3i, 4b, 4f, 4g, 4h and 4l against P.  vulgaris and the compounds 3b, 3d, 3h, 3i, 3k, 4b, 4d, 4g, 4h and 4i display maximum activity against A. niger.
